[34E1-34E1];[34E5-34E5];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
34E1;34E5
Breakpoint based on release 3 sequence coordinate from Thibault et al., 2004, Supplementary Table 2 (FBrf0174227) or 3 (FBrf0174228), converted to release 5 coordinate.
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Inferred to overlap with: Df(2L)BSC694.
Inferred to overlap with: Df(2L)b87e25.
Inferred to overlap with: Df(2L)BSC252.
Df(2L)BSC345 is heterozygous viable.
The presence of P+PBac{XP5.RB3}BSC345 was verified using the PCR methods and primers described in FBrf0175003 with the substitution of the primer 5'-CCAATGCGTTTATTTCAGGTCACG-3' for the RB3' plus or RB3' minus primer in the Hybrid PCR protocol in the Supplementary Methods.
Exelixis, Inc. determined the insertion site of P{XP}d03477 to be at Release 3 genomic coordinate 13860811 on chromosome arm 2L. This corresponds to 34E1 on both the Release 3 and 5 genome maps. The predicted position of PBac{RB}e02962 on the Release 5 map is 34E5. Consequently, the cytological breakpoints of Df(2L)BSC345 are predicted to be 34E1;34E5.